Literature DB >> 10804294

Biodistribution of boron concentration on melanoma-bearing hamsters after administration of p-, m-, o-boronophenylalanine.

J Hiratsuka1, K Yoshino, H Kondoh, Y Imajo, Y Mishima.   

Abstract

Although p-boronophenylalanine (p-BPA), a boronate analogue of tyrosine, has proven to be one of the most successful compounds for boron neutron capture therapy (BNCT) of malignant melanoma, the selective uptake mechanism of this compound into melanoma cells is not well understood. Therefore, the relationship between the structure of BPA and its specific affinity to melanoma cells appears worthy of investigation. In the present study, m- and o-boronophenylalanine (m- and o-BPA) were administered to melanoma-bearing hamsters and their uptake was measured. The time courses (0.5, 2.0, 4.0 and 48.0 h) of boron concentrations in melanoma, normal skin, and blood were determined in male Syrian (golden) hamsters bearing Greene's melanomas following a single intraperitoneal injection of either p-, m- or o-BPA (100 mg/kg of BPA fructose in 1.0 ml of saline). The boron concentrations in these tissues were measured by inductively coupled plasma-atomic emission spectrometry (ICP-AES). In melanoma, the order of boron uptake was p- > m- > o-BPA at all time points, and the boron concentrations obtained with p-BPA and m-BPA resembled each other in that they had a peak at 2 h after administration and decreased with time. The melanoma/skin boron concentration ratio of p-BPA had a peak at 4 h after administration and the ratio ranged between 7/1 and 8/1. On the other hand, m-BPA and o-BPA had a peak at 2 h and their ratios ranged between 4/1 and 5/1. The difference in the accumulations of p-BPA and m-BPA could be due to a difference in the property of p-BPA as a tyrosine analogue for melanin synthesis. The accumulation of m-BPA into melanoma might indicate the baseline level of metabolism-related amino acid transport. Our experimental findings indicate that this melanin synthesis, or the structural analogy between the boron compound and tyrosine as a precursor of melanin, is an important factor in the increased accumulation of p-BPA in melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10804294      PMCID: PMC5926464          DOI: 10.1111/j.1349-7006.2000.tb00965.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  12 in total

1.  A spontaneous melanoma in the hamster with a propensity for amelanotic alteration and sarcomatous transformation during transplantation.

Authors:  H S GREENE
Journal:  Cancer Res       Date:  1958-05       Impact factor: 12.701

2.  [Selective affinity of 10B1-paraboronophenylalanine-HCl to malignant melanoma: thermal neutron capture therapy].

Authors:  M Tsuji; M Ichihashi; Y Mishima
Journal:  Nihon Hifuka Gakkai Zasshi       Date:  1983-06

3.  The relative biological effectiveness in V79 Chinese hamster cells of the neutron capture reactions in boron and nitrogen.

Authors:  D Gabel; R G Fairchild; B Larsson; H G Börner
Journal:  Radiat Res       Date:  1984-05       Impact factor: 2.841

4.  Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound.

Authors:  Y Mishima; C Honda; M Ichihashi; H Obara; J Hiratsuka; H Fukuda; H Karashima; T Kobayashi; K Kanda; K Yoshino
Journal:  Lancet       Date:  1989-08-12       Impact factor: 79.321

5.  Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy.

Authors:  H Hatanaka; Y Nakagawa
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-03-30       Impact factor: 7.038

6.  The pharmacokinetics of p-Boronophenylalanine.fructose in human patients with glioma and metastatic melanoma.

Authors:  J L Mallesch; D E Moore; B J Allen; W H McCarthy; R Jones; W A Stening
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-03-30       Impact factor: 7.038

7.  Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma.

Authors:  J A Coderre; J D Glass; R G Fairchild; P L Micca; I Fand; D D Joel
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

8.  Neutron capture therapy of a rat glioma using boronophenylalanine as a capture agent.

Authors:  K Z Matalka; R F Barth; A E Staubus; M L Moeschberger; J A Coderre
Journal:  Radiat Res       Date:  1994-01       Impact factor: 2.841

9.  Local control of subcutaneous murine melanoma xenografts in nude mice by neutron capture therapy.

Authors:  B J Allen; S Corderoy-Buck; J L Mallesch; K Crotty; D E Moore
Journal:  Melanoma Res       Date:  1992-11       Impact factor: 3.599

10.  RBEs of thermal neutron capture therapy and 10B(n, alpha)7 Li reaction on melanoma-bearing hamsters.

Authors:  J Hiratsuka; M Kono; Y Mishima
Journal:  Pigment Cell Res       Date:  1989 Jul-Aug
View more
  2 in total

1.  Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors.

Authors:  Shinji Kawabata; Weilian Yang; Rolf F Barth; Gong Wu; Tianyao Huo; Peter J Binns; Kent J Riley; Owendi Ongayi; Vijay Gottumukkala; M Graça H Vicente
Journal:  J Neurooncol       Date:  2010-09-17       Impact factor: 4.130

2.  Evaluation of 3-Borono-l-Phenylalanine as a Water-Soluble Boron Neutron Capture Therapy Agent.

Authors:  Naoya Kondo; Fuko Hirano; Takashi Temma
Journal:  Pharmaceutics       Date:  2022-05-22       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.